MFA-370 Phase I/II trial

Urothelial bladder cancer is one of the world’s most aggressive cancers, current treatments can be tough to tolerate. MFA-370 is planned to be a simple oral tablet developed to eliminate tumors safely, with few if any side effects.

Ectin has now obtained regulatory approvals in Sweden, Denmark, Lithuania, as well as CTA/EC approval in Germany for its combined Phase I/II clinical trial of MFA-370.

How it all started

When clinical urologist Dr Christer Edlund, witnessed the remarkable remission of terminal inoperable urothelial bladder cancer, some described it as a ‘medical miracle’. But research revealed that the patient had, in recent months, been prescribed a standard medication for a random parasitic infection he had picked up – in addition to his regular treatments. This was the clue that started the development of MFA-370.

Repurposing tried, tested and trusted drugs

MFA-370 is a combination of a medication from that substance family, together with one other standard, well-established drug. Both are tried, tested and trusted treatments that have already undergone large-scale clinical trials.

Quality of life in a critical time

End-stage urothelial bladder cancer patients often face treatment options with severe side effects, MFA-370 is planned to be a simple oral tablet offering hope of improved quality of life during the most painful, challenging periods of their lives.

High potential

      • Already demonstrated efficacy in preclinical results and ‘patient zero’ case
      • Few if any potential side effects in treatments making up MFA-370
      • Oral administration (tablet) means reduced social costs and increased quality -of-life

Prostate, breast and
colorectal cancer cell results

In addition to MFA-370 showing positive preclinical results in metastatic urothelial bladder cancer, it has also eliminated prostate, breast and colorectal cancer cells in preclinical tests too.

Planned Phase I/II study in metastatic bladder cancer

Ectin has obtained all regulatory approvals in Sweden, Denmark, Lithuania, as well as CTA/EC approval in Germany for its combined Phase I/II clinical trial of its drug candidate MFA-370 for the treatment of metastatic urothelial bladder cancer. The company will initiate the study when financing is in place.

Read more about metastatic urothelial bladder cancer 

A robust IP position

Ectin Research prioritizes intellectual property rights and has sought patent protection for different aspects of its technology in several parts of the world.

We currently have approved and issued patents protecting our technology in major bladder cancer markets including 22 European countries, the  US, Canada and Australia.